Houston’s Science and Medicine Communities love Supporting The Arts and Sports

Barron’s Medical Journal Reporting From Houston Texas Museum District, Galleria, And Reliant Park Houston:

---

Houston ( AP ) Diamond in Your Life Report: Houston’s Science and Medicine Communities love Supporting The Arts and Sports.

---

Houston ( AP ) Diamond in Your Life Report: Barron’s Medical Journal has known for a long time that the folks that work in science and medicine love supporting the arts and sports. One city that has it all is Houston Texas, Yes Houston has one of the great art scenes, with the Texans entering the playoffs for a second year and the Chevron Marathon Barron’s Medical Journal Diamond in Your Life Report: visited these hot spots in Houston.

GenNXeix Biotech To Honor NIH Francis S. Collins, M.D., Ph.D.

Barrons Medical Journal Reporting From San Francisco J.P. Morgan Healthcare Conference:

---

San Fransisco , (GLOBE NEWSWIRE via COMTEX) -- GenNXeix Biotech Inc announced today at the J.P. Morgan Healthcare Conference in San Francisco Feb 1 /PRNewswire/

---

San Fransisco CA ( AP ) — GenNXeix Biotech Inc is one of the leading supporters of GenNXeix Genomics Science Black Tie Ball To Honor National Institute of Health Chief Executive Officer Francis S. Collins, M.D., Ph.D.

to take place June 15, 2013 at the Omni Hotel in Houston Texas. Proceeds from the event will support American Cancer Society, to initiate the development and deployment of promising new Genomics Science and therapies to improve and save patient lives. The celebrity chairperson of The Genomics Science Black Tie Ball is Congress Women Shelia Jackson Lee. GenNXeix Biotech will also honor

Crystle Stewart Miss USA 2008 And Breast Cancer Survivor GenNXeix Biotech Inc And Angel Mines songwriter and music producer has wrote a Breast Cancer Song "Light As A Feather" To Be Recorded Live At GenNXeix Genomics Science Black Tie Ball and Sold On iTunes for One dollar all funds will be donated to American Cancer Society. “As a Biotech Engineering company, GenNXeix Biotech Inc is honored to support The GenNXeix Genomics Science Black Tie Ball ,” says Robert Graham, Executive Vice President of GenNXeix Biotech Inc North America. “It is only through the medical community and philanthropic outreach that we can complete our mission, which is putting into the hands of healthcare professionals the tools they need to treat breast cancer and to improve, prolong and save patient lives.” This is one of the rarest opportunities for biotechnology, pharmaceutical, and medical device companies to network about where they've been and where they're headed, so it pays to take notice and attend. The first and only freestanding Genomics Biotech Engineering center of its kind in Houston, The GenNXeix Biotech Inc, is hosting the event, as well as serving as a major sponsor Lilly. “Genomics Science Black Tie Ball was put together with the same principles for why we started GenNXeix Biotech Inc on the most humanistic level,” says Rose Conrad., Founder and CEO. “It is about giving back to people and the community, and bringing genomics cancer care to the next level. It is in harmony with GenNXeix Biotech Inc philosophy, which emphasizes caring for the whole person, not just treating their disease. The most fundamental understanding of the preciousness of life is what has driven us to pursue our dream to help people with breast cancer–to help them live fuller lives while under our care and ideally once their disease is defeated.”

FORWARD LOOKING STATEMENTS -- Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of

GenNXeix Biotech Ins as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. CONTACT: For further information, please contact: Cathy Monroe Director Of Fund Raising 281-661-6002 Gennxeix45@gmail.com GenNXeix Biotech Inc Houston Galleria Houston Texas(USA) ( C) Copyright 2013 GenNXeix Biotech, Inc. All rights reserved

No One Dies Of Breast Cancer –Patients Die Because Breast Cancer Spreads To Their lungs

Barrons Medical Journal Reporting From Duke University Medical School Durham, NC

---

---

No One Dies Of Breast Cancer –Patients Die Because Breast Cancer Spreads To Their lungs

---

Durham, NC ( AP ) Now that the Fiscal Cliff is all finish it is now time to focus our attention to stopping Breast Cancer in its Tracks. To find a cure we must first

stop folks from dying from breast cancer. The spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. The process by which breast cancer spreads -- or metastasizes is where Barrons Medical Journal is going to focus. Metastasis was long thought as a late event in breast cancer progression, With Genomics we now shown metastasis to be an early event that is dependent on HIF-1. HIF-1 protein controls genes that enable cells to survive in low oxygen, like cells in solid breast tumors.

In order for breast cancer cells to spread to lungs, they must leave the breast,

enter blood vessels that lead to the lungs, and exit those same vessels. "Blood vessels are pretty tight; a cell has to work pretty hard to get through the vessel wall. How this process works is breast cancer cells turn on genes called ANGPTL4, ANGPTL4, helps breast cancer to travel through blood vessel walls.

Research is now being performed with Genomics. The Gennxeix Biotech Team found by injecting these cells either with normal or "knocked-down" levels of ANGPTL4 into mice and examining their lungs. Cells lacking HIF-1 and containing extra ANGPTL4 were better able to invade the lungs than cells without extra ANGPTL4.

Barron Medical Journal Interviewed Gennxeix Biotech Chief Science Officer. Gennxeix Biotech found involvement in human breast cancer progression, based on the analysis of human breast cancer biopsies and experimental animal mice models. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Gennxeix discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells

increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT. In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of

VEGF expression. GenNXeix demonstrate that HER2 signaling induced by overexpression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (FKBP-rapamycin-associated protein)
Gennxeix concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1 treatments